Approaches to the treatment of anaemia in patients with chronic heart failure

Heart Failure Reviews

Volumn 13, Issue 4, 2008, Pages 431-438

  Murphy, Clare L ^a   McMurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Rationale for treatment of anaemia

Indexed keywords

ANTINEOPLASTIC AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; DIURETIC AGENT; ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; FERROUS GLUCONATE; FOLIC ACID; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR INHIBITOR; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXYGEN; PLACEBO; PROTEIN INHIBITOR; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DEATH; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; EVIDENCE BASED MEDICINE; FUNCTIONAL ASSESSMENT; HEALTH STATUS; HEART FAILURE; HEMODYNAMICS; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; IRON DEFICIENCY; IRON METABOLISM; IRON THERAPY; MONOTHERAPY; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SYMPTOMATOLOGY; TISSUE OXYGENATION; VASOCONSTRICTION;

ANEMIA; CHRONIC DISEASE; ERYTHROPOIETIN; HEART FAILURE; HEMATINICS; HUMANS; IRON;

EID: 43749083695     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-008-9085-y     Document Type: Article

References (49)

1. Anand IS, Chandrashekhar Y, Ferrari R, Poole-Wilson PA, Harris PC (1993) Pathogenesis of oedema in chronic severe anaemia: Studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J 70:357-362
2. Anand IS, Chandrashekhar Y, Wander GS, Chawla LS (1995) Endothelium-derived relaxing factor is important in mediating the high output state in chronic severe anemia. J Am Coll Cardiol 25:1402-1407
3. O'Meara E, Murphy C, McMurray JJ (2004) Anemia and heart failure. Curr Heart Fail Rep 1:176-182
4. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J (2002) Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 39:1780-1786
5. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R (2002) Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: A population-based study. J Am Soc Nephrol 13:1928-1936
6. Tanner H, Moschovitis G, Kuster GM, Hullin R, Pfiiffner D, Hess OM, Mohacsi P (2002) The prevalence of anemia in chronic heart failure. Int J Cardiol 86:115-121
7. Ezekowitz JA, McAlister FA, Armstrong PW (2003) Anemia is common in heart failure and is associated with poor outcomes: Insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 107:223-225
8. Kosiborod M, Smith GL, Radford MJ, Foody JM, Krumholz HM (2003) The prognostic importance of anemia in patients with heart failure. Am J Med 114:112-119
9. Mozaffarian D, Nye R, Levy WC (2003) Anemia predicts mortality in severe heart failure: The prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol 41:1933-1939
10. Anand I, McMurray JJ, Whitmore J, Warren M, Pham A, McCamish MA, Burton PB (2004) Anemia and its relationship to clinical outcome in heart failure. Circulation 110:149-154
11. Maggioni AP, Opasich C, Anand I, Barlera S, Carbonieri E, Gonzini L, Tavazzi L, Latini R, Cohn J (2005) Anemia in patients with heart failure: Prevalence and prognostic role in a controlled trial and in clinical practice. J Card Fail 11:91-98
12. Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A, Chiang YT, Aknay N, Maggioni AP, Opasich C, Latini R, Cohn JN (2005) Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: Results from Val-HeFT. Circulation 112:1121-1127
13. Kosiborod M, Curtis JP, Wang Y, Smith GL, Masoudi FA, Foody JM, Havranek EP, Krumholz HM (2005) Anemia and outcomes in patients with heart failure: A study from the National Heart Care Project. Arch Intern Med 165:2237-2244
14. O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Lang CC, Roger SD, Young JB, Solomon SD, Granger CB, Ostergren J, Olofsson B, Michelson EL, Pocock S, Yusuf S, Swedberg K, Pfeffer MA (2006) CHARM Committees and Investigators. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation 113:986-994
15. Komajda M, Anker SD, Charlesworth A, Okonko D, Metra M, Di Lenarda A, Remme W, Moullet C, Swedberg K, Cleland JG, Poole-Wilson PA (2006) The impact of new onset anaemia on morbidity and mortality in chronic heart failure: Results from COMET. Eur Heart J 27:1440-6144
16. Witte KK, Desilva R, Chattopadhyay S, Ghosh J, Cleland JG, Clark AL (2004) Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J 147:924-930
17. Androne AS, Katz SD, Lund L, LaManca J, Hudaihed A, Hryniewicz K, Mancini DM (2003) Hemodilution is common in patients with advanced heart failure. Circulation 107:226-229
18. van der Meer P, Lipsic E, Westenbrink BD, van de Wal RM, Schoemaker RG, Vellenga E, van Veldhuisen DJ, Voors AA, van Gilst WH (2005) Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 112:1743-1747
19. Okonko DO, Van Veldhuisen DJ, Poole-Wilson PA, Anker SD (2005) Anaemia of chronic disease in chronic heart failure: The emerging evidence. Eur Heart J 26:2213-2214
20. Westenbrink BD, Visser FW, Voors AA, Smilde TD, Lipsic E, Navis G, Hillege HL, van Gilst WH, van Veldhuisen DJ (2007) Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J 28:166-171
21. Westenbrink BD, Voors AA, van Veldhuisen DJ (2007) Is anemia in chronic heart failure caused by iron deficiency? J Am Coll Cardiol 49:2301-2302
22. Berry C, Norrie J, Hogg K, Brett M, Stevenson K, McMurray JJ (2006) The prevalence, nature, and importance of hematologic abnormalities in heart failure. Am Heart J 151:1313-1321
23. Gossmann J, Burkhardt R, Harder S, Lenz T, Sedlmeyer A, Klinkhardt U, Geiger H, Scheuermann EH (2001) Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway. Kidney Int 60:83-86
24. Freudenthaler SM, Schreeb K, Körner T, Gleiter CH (1999) Angiotensin II Increases erythropoietin production in healthy human volunteers. Eur J Clin Invest 29:816-823
25. Pratt MC, Lewis-Barned NJ, Walker RJ, Bailey RR, Shand BI, Livesey J (1992) Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers. Br J Clin Pharmacol 34:363-365
26. Chatterjee B, Nydegger UE, Mohacsi P (2000) Serum erythropoietin in heart failure patients treated with ACE-inhibitors or AT(1) antagonists. Eur J Heart Fail 2:393-398
27. Ishani A, Weinhandl E, Zhao Z, Gilbertson DT, Collins AJ, Yusuf S, Herzog CA (2005) Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 45:391-399
28. Jelkmann W (2007) Erythropoietin after a century of research: Younger than ever. Eur J Haematol 78:183-205
29. Silverberg DS, Wexler D, Blum M, Wollman Y, Schwartz D, Sheps D, Keren G, Iaina A (2004) The interaction between heart failure, renal failure and anemia - the cardio-renal anemia syndrome. Blood Purif 22:277-284
30. Sytkowski AJ (2007) Does erythropoietin have a dark side? Epo signaling and cancer cells. Sci STKE 2007:pE38
31. Westenbrink BD, Lipsic E, van der Meer P, van der Harst P, Oeseburg H, Du Marchie Sarvaas GJ, Koster J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG (2007) Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 28:2018-2027
32. Saglam F, Cavdar C, Uysal S, Cavdar Z, Camsari T (2007) Effect of intravenous iron sucrose on oxidative stress in peritoneal dialysis patients. Ren Fail 29:849-854
33. van Veldhuisen DJ, McMurray JJ (2007) RED-HF Executive Committee. Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. Eur J Heart Fail 9:110-112
34. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, Shapira I, Gavish D, Baruch R, Koifman B, Kaplan C, Steinbruch S, Iaina A (2000) The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35:1737-1744
35. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S, Iaina A (2001) The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: A randomized controlled study. J Am Coll Cardiol 37:1775-1780
36. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS (2003) Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107:294-299
37. Cleland JG, Sullivan JT, Ball S, Horowitz JD, Agoram B, Rosser D, Yates W, Tin L, Fuentealba P, Burton PB (2005) Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: A pharmacokinetic and pharmacodynamic investigation. J Cardiovasc Pharmacol 46:155-161
38. Ponikowski P, Anker SD, Szachniewicz J, Okonko D, Ledwidge M, Zymlinski R, Ryan E, Wasserman SM, Baker N, Rosser D, Rosen SD, Poole-Wilson PA, Banasiak W, Coats AJ, McDonald K (2007) Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: A randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 49:753-762
39. van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P (2007) Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 28:2208-2216
40. Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P; on behalf of the Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group (2008) Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. [Epub ahead of print]
41. Haurani FI (2006) Hepcidin and the anemia of chronic disease. Ann Clin Lab Sci 36:3-6
42. Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med. 352:1011-1023
43. Felker GM, Gattis WA, Leimberger JD, Adams KF, Cuffe MS, Gheorghiade M, O'Connor CM (2003) Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol 92:625-628
44. Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, Tsagalou EP, Maroulidis GD, Alexopoulos GP, Kanakakis JE, Anastasiou-Nana MI (2006) Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 48:2485-2489
45. Bolger AP, Bartlett FR, Penston HS, O'Leary J, Pollock N, Kaprielian R, Chapman CM (2006) Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 48:1225-1227
46. Toblli JE, Lombraña A, Duarte P, Di Gennaro F (2007) Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50:1657-1665
47. Beck-da-Silva L, Rohde LE, Pereira-Barretto AC, de Albuquerque D, Bocchi E, Vilas-Boas F, Moura LZ, Montera MW, Rassi S, Clausell N (2007) Rationale and design of the IRON-HF study: A randomized trial to assess the effects of iron supplementation in heart failure patients with anemia. J Card Fail 13:14-17
48. Macdougall IC (2006) Recent advances in erythropoietic agents in renal anemia. Semin Nephrol 26:313-318
49. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, Nizet V, Johnson RS (2007) Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 117:1926-1932